Literature DB >> 31593596

Guidance for the Evaluation of Tuberculosis Diagnostics That Meet the World Health Organization (WHO) Target Product Profiles: An Introduction to WHO Process and Study Design Principles.

Claudia M Denkinger1,2, Samuel G Schumacher1, Christopher Gilpin3, Alexei Korobitsyn3, William A Wells4, Madhukar Pai5, Mariska Leeflang6, Karen R Steingart7, Michelle Bulterys1,8, Holger Schünemann9, Philippe Glaziou3, Karin Weyer3.   

Abstract

Existing high-priority target product profiles (TPPs) of the World Health Organization (WHO) establish important needs for tuberculosis (TB) diagnostic development. Building on this earlier work, this guidance series aims to provide study guidance for performing accuracy studies of novel diagnostic products that may meet the 4 high-priority WHO TPPs and thus enable adequate evidence generation to inform a WHO evidence review process. Diagnostic accuracy studies represent a fundamental step in the validation of all tests. Unfortunately, such studies often have limitations in design, execution, and reporting, leading to low certainty of the evidence about true test performance, which can delay or impede policy and scale-up decisions. This introductory paper outlines the following: (1) the purpose of this series of papers on study guidance; (2) WHO evidence needs and process for the development of policy guidelines for new TB diagnostic tests; and (3) study design considerations, ie, general diagnostic study considerations, intended use of test and role in the clinical pathway, choice of population and setting, index-test specific issues, suitable reference standard and comparators, study flow and specimen issues, and finally key issues beyond accuracy that should be considered. The other 4 papers in this series will provide more detailed guidance for each of the 4 WHO high-priority TPPs. By increasing the clarity around the clinical evaluation needs for tests that have the potential to meet the TPP specifications, we hope to support harmonized evidence generation and enable the WHO review process towards meeting the WHO End TB Strategy targets for reducing the incidence and mortality associated with TB.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  TPPs; WHO End TB strategy; diagnostics; target product profiles; tuberculosis

Mesh:

Substances:

Year:  2019        PMID: 31593596     DOI: 10.1093/infdis/jiz097

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Performance of the Roche cobas MTB Assay for the Molecular Diagnosis of Pulmonary Tuberculosis in a High HIV Burden Setting.

Authors:  Lesley Scott; Anura David; Lyndel Govender; Jan Furrer; Modiehi Rakgokong; Ziyaad Waja; Neil Martinson; Gabriel Eisenberg; Elizabeth Marlowe; Wendy Stevens
Journal:  J Mol Diagn       Date:  2020-08-01       Impact factor: 5.568

2.  Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid.

Authors:  Margaretha de Vos; Lesley Scott; Anura David; Andre Trollip; Harald Hoffmann; Sophia Georghiou; Sergio Carmona; Morten Ruhwald; Wendy Stevens; Claudia M Denkinger; Samuel G Schumacher
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

3.  Validation of Differentially Expressed Immune Biomarkers in Latent and Active Tuberculosis by Real-Time PCR.

Authors:  Prem Perumal; Mohamed Bilal Abdullatif; Harriet N Garlant; Isobella Honeyborne; Marc Lipman; Timothy D McHugh; Jo Southern; Ronan Breen; George Santis; Kalaiarasan Ellappan; Saka Vinod Kumar; Harish Belgode; Ibrahim Abubakar; Sanjeev Sinha; Seshadri S Vasan; Noyal Joseph; Karen E Kempsell
Journal:  Front Immunol       Date:  2021-03-16       Impact factor: 7.561

4.  Asia emerges as a hotbed of diagnostic innovations for tuberculosis.

Authors:  Jacob Bigio; Wayne van Gemert; Brian Kaiser; Brenda Waning; Madhukar Pai
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2021-08-25

5.  Biomarkers That Correlate with Active Pulmonary Tuberculosis Treatment Response: a Systematic Review and Meta-analysis.

Authors:  Claudia M Denkinger; Mikashmi Kohli; Alexandra J Zimmer; Federica Lainati; Nathaly Aguilera Vasquez; Carole Chedid; Sean McGrath; Andrea Benedetti; Emily MacLean; Morten Ruhwald
Journal:  J Clin Microbiol       Date:  2021-12-15       Impact factor: 5.948

6.  Metagenomic DNA sequencing to quantify Mycobacterium tuberculosis DNA and diagnose tuberculosis.

Authors:  Adrienne Chang; Omary Mzava; Liz-Audrey Kounatse Djomnang; Joan Sesing Lenz; Philip Burnham; Peter Kaplinsky; Alfred Andama; John Connelly; Christine M Bachman; Adithya Cattamanchi; Amy Steadman; Iwijn De Vlaminck
Journal:  Sci Rep       Date:  2022-10-10       Impact factor: 4.996

Review 7.  Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update.

Authors:  Michelle A Bulterys; Bradley Wagner; Maël Redard-Jacot; Anita Suresh; Nira R Pollock; Emmanuel Moreau; Claudia M Denkinger; Paul K Drain; Tobias Broger
Journal:  J Clin Med       Date:  2019-12-31       Impact factor: 4.241

8.  High sensitivity and specificity of a 5-analyte protein and microRNA biosignature for identification of active tuberculosis.

Authors:  Jessica L Pedersen; Simone E Barry; Nilesh J Bokil; Magda Ellis; YuRong Yang; Guangyu Guan; Xiaolin Wang; Alen Faiz; Warwick J Britton; Bernadette M Saunders
Journal:  Clin Transl Immunology       Date:  2021-06-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.